BR112017016428B1 - Composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável - Google Patents

Composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável Download PDF

Info

Publication number
BR112017016428B1
BR112017016428B1 BR112017016428-0A BR112017016428A BR112017016428B1 BR 112017016428 B1 BR112017016428 B1 BR 112017016428B1 BR 112017016428 A BR112017016428 A BR 112017016428A BR 112017016428 B1 BR112017016428 B1 BR 112017016428B1
Authority
BR
Brazil
Prior art keywords
pyridin
amino
imidazo
chloro
phenoxy
Prior art date
Application number
BR112017016428-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017016428A2 (pt
Inventor
Hakan Mellstedt
Styrbjörn Byström
Jan Vagberg
Elisabeth OLSSON
Original Assignee
Kancera Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kancera Ab filed Critical Kancera Ab
Publication of BR112017016428A2 publication Critical patent/BR112017016428A2/pt
Publication of BR112017016428B1 publication Critical patent/BR112017016428B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112017016428-0A 2015-02-02 2016-02-01 Composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável BR112017016428B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15153394 2015-02-02
EP15153394.0 2015-02-02
PCT/EP2016/052091 WO2016124553A1 (en) 2015-02-02 2016-02-01 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity

Publications (2)

Publication Number Publication Date
BR112017016428A2 BR112017016428A2 (pt) 2018-04-10
BR112017016428B1 true BR112017016428B1 (pt) 2023-10-24

Family

ID=52449976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016428-0A BR112017016428B1 (pt) 2015-02-02 2016-02-01 Composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável

Country Status (13)

Country Link
US (1) US10550113B2 (https=)
EP (1) EP3253754B1 (https=)
JP (1) JP6629884B2 (https=)
KR (1) KR102493943B1 (https=)
CN (1) CN107567445B (https=)
AU (1) AU2016214492B2 (https=)
BR (1) BR112017016428B1 (https=)
CA (1) CA2973773C (https=)
ES (1) ES2875737T3 (https=)
IL (1) IL253380B (https=)
MX (1) MX374552B (https=)
WO (1) WO2016124553A1 (https=)
ZA (1) ZA201705933B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
EP3481824B1 (en) * 2016-07-11 2021-10-20 Kancera AB 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
JP7378267B2 (ja) 2018-11-12 2023-11-13 東ソー株式会社 コバルト錯体、その製造方法、及びコバルト含有薄膜の製造方法
JP7641902B2 (ja) 2019-01-29 2025-03-07 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア 緑内障の新規治療法
CN112574176B (zh) * 2019-09-27 2024-03-15 隆泰申医药科技(南京)有限公司 一种杂芳基类化合物及其应用
CN117049977A (zh) * 2023-08-16 2023-11-14 四川伊诺达博医药科技有限公司 一种n-乙基-2-(4-甲酰基苯基)乙酰胺的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
SE0202464D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
CN101830899A (zh) 2004-12-23 2010-09-15 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物,它们的制备及作为药剂的应用
JP2008525355A (ja) 2004-12-23 2008-07-17 エフ.ホフマン−ラ ロシュ アーゲー ベンズアミド誘導体、これらの製造及び医薬剤としての使用。
AU2006209117B2 (en) 2005-01-28 2009-12-10 Daewoong Pharmaceutical Co., Ltd. Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
EP1891069A1 (en) 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US8088761B2 (en) 2005-12-22 2012-01-03 Cancer Research Technology Limited Enzyme inhibitors
WO2007083978A1 (en) 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
WO2008121063A1 (en) 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[ 4,5-b]pyridine-7-carboxamides 704
WO2008121064A1 (en) 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
WO2009001021A1 (en) 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
CA2716947A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
US20120295915A1 (en) 2009-11-24 2012-11-22 Chaudhari Amita M Azabenzimidazoles as fatty acid synthase inhibitors
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos

Also Published As

Publication number Publication date
KR20170113629A (ko) 2017-10-12
CA2973773C (en) 2023-10-17
BR112017016428A2 (pt) 2018-04-10
JP2018507255A (ja) 2018-03-15
MX2017009600A (es) 2017-11-22
EP3253754B1 (en) 2021-03-31
EP3253754A1 (en) 2017-12-13
CN107567445A (zh) 2018-01-09
WO2016124553A1 (en) 2016-08-11
MX374552B (es) 2025-03-06
IL253380A0 (en) 2017-09-28
HK1247923A1 (zh) 2018-10-05
AU2016214492B2 (en) 2020-05-07
IL253380B (en) 2021-07-29
KR102493943B1 (ko) 2023-01-31
CN107567445B (zh) 2021-06-29
JP6629884B2 (ja) 2020-01-15
CA2973773A1 (en) 2016-08-11
US20180002329A1 (en) 2018-01-04
ZA201705933B (en) 2018-12-19
US10550113B2 (en) 2020-02-04
AU2016214492A1 (en) 2017-08-24
ES2875737T3 (es) 2021-11-11

Similar Documents

Publication Publication Date Title
BR112017016428B1 (pt) Composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável
JP7369458B2 (ja) ヒストンデアセチラーゼ6阻害剤としての1,2,4-オキサジアゾール誘導体
WO2018045956A1 (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
KR20190092542A (ko) Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물 및 이의 사용 방법
JP2021176847A (ja) 置換5員および6員複素環式化合物、その調製方法、薬剤の組み合わせおよびその使用
JPWO2016208592A1 (ja) 二環性複素環アミド誘導体
US11008318B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
BR112020007632A2 (pt) composto, composição farmacêutica, método para inibir um dentre ou tanto ehmt1 quanto ehmt2, método para prevenir ou tratar um distúrbio sanguíneo, método para prevenir ou tratar um câncer e uso do composto
US11660303B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
RU2797613C2 (ru) Производные 1,2,4-оксадиазола в качестве ингибиторов гистондезацетилазы 6
HK1247923B (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
CN120518607A (zh) 并环类衍生物抑制剂、其制备方法和应用
BR112020010534B1 (pt) Derivados de 1,2,4-oxadiazol, seus usos como inibidores de histona desacetilase 6 e composição farmacêutica compreendendo os mesmos
BR112017025356B1 (pt) Composto, composição farmacêutica, e, uso para a fabricação de um medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2016, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 9A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2812 DE 26-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.